Biopure | Jotup

Protein Evolution, Inc. and Basecamp Research Aim to Make Polyurethane and Nylon Infinitely Recyclable with Expanded Strategic Collaboration

Retrieved on:

Wednesday, January 24, 2024

Entrepreneurship, Athleisure, Biodiversity, Evolutionism, Gene, AI, Map, Carbon, Enzyme, Protein, Research, Biopure, Nature, Fine chemical

Protein Evolution’s Biopure™ technology uses AI-designed enzymes to currently break down polyester waste and transform it into the building blocks of new polyester.

Key Points:

Protein Evolution’s Biopure™ technology uses AI-designed enzymes to currently break down polyester waste and transform it into the building blocks of new polyester.
By leveraging Basecamp Research’s biodiversity mapping system, Protein Evolution will unlock previously inaccessible enzymes to break down polyurethane and polyamide waste.
Polyurethane, commonly found in products like spandex, mattresses, sofas, car seats, and insulation panels, poses a substantial recycling challenge.
By combining Basecamp Research’s platform with Protein Evolution’s scale-up expertise, this collaboration will accelerate the development timelines of novel enzymes for biological recycling from years to months.

Protein Evolution, Inc. and Fashion Sustainability Pioneer, Stella McCartney, Debut The World’s First Garment Made Using Biological Recycling

Retrieved on:

Friday, December 1, 2023

COP28, Entrepreneurship, Conference, Biopure, Partnership, Evolutionism, Paul McCartney, LVMH, Textile, Stella McCartney, Clothing, Petroleum

“Today marks a pivotal moment in the move towards textile-to-textile circularity in the fashion industry,” said Connor Lynn, Co-Founder and Chief Business Officer of Protein Evolution.

Key Points:

“Today marks a pivotal moment in the move towards textile-to-textile circularity in the fashion industry,” said Connor Lynn, Co-Founder and Chief Business Officer of Protein Evolution.
Biopure is capable of handling a variety of waste streams, from plastic bottles and clam-shells, to industrial textiles and garments.
“Anybody who knows me knows that I hate waste, which is why I am so thrilled about our collaboration with Protein Evolution,” said Stella McCartney.
“It’s remarkable what the company has achieved in less than a year of this collaboration with our partner Stella McCartney.

AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long-Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism

Retrieved on:

Tuesday, October 4, 2022

This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.

Key Points:

This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.
In addition, the Company will file for both orphan drug and rare pediatric disease designation with the FDA.
Congenital hyperinsulinism is a rare disease that affects newborns and results in persistent hypoglycemia which can lead to serious neurological complications including seizures and brain damage.
"We are honored to receive this Phase IIB SBIR grant from the NIH.

Creating a clean-label soy protein for Canada’s plant-based food and ingredients sector

Retrieved on:

Wednesday, July 6, 2022

Todays announcement highlights how the Protein Industries Cluster is creating new opportunities to cement Canada as a global leader in the plant-based food and ingredients sector, said the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry.

Key Points:

Todays announcement highlights how the Protein Industries Cluster is creating new opportunities to cement Canada as a global leader in the plant-based food and ingredients sector, said the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry.
It will be the first facility in Canada to produce soy protein isolate, a critical food ingredient used in baby formula, athletic supplements, plant-based food products and many other applications.
Together with industry, Protein Industries Canada has committed more than $485 million to growing Canadas plant-based food and ingredients sector.
Their products include soy protein isolates, soy protein powders, textured soy proteins and soy flours.

Watson-Marlow announces details of the new U.S. manufacturing facility bringing them closer to customers in the region

Retrieved on:

Wednesday, October 20, 2021

FTSE, Biotechnology, Spirax-Sarco Engineering, Growth, FOR, Multimedia, Biopure, United Kingdom, Drinking water, Industry, Group, Engineering, Solution, Carbon, Food, Company, Renewable energy, Chemical

Part of Spirax-Sarco Engineering plc, a FTSE100 Company, Watson-Marlow specializes in high-quality fluid management solutions for the life sciences and process industries.

Key Points:

Part of Spirax-Sarco Engineering plc, a FTSE100 Company, Watson-Marlow specializes in high-quality fluid management solutions for the life sciences and process industries.
This significant investment in the expansion of its manufacturing capacity will support the Company's future growth in the Americas.
Located in Devens, Massachusetts, U.S.A., the 150,000 square foot (14,000 square metres) facility will be close to the life sciences hub in the Cambridge/Boston area.
"The new U.S. facility is an important milestone in the Watson-Marlow company history and marks a significant commitment to serving our customers in the Americas region."